Study Comparing RT With Cetuximab + Xevinapant to RT With Cetuximab-placebo in Patients With Head and Neck Cancer

NCT05930938 · clinicaltrials.gov ↗

PHASE3

Phase

TERMINATED

Status

19

Enrollment

OTHER

Sponsor class

Stopped toxicity

Conditions

Squamous Cell Carcinoma of the Head and Neck

Interventions

DRUG: Xevinapant
DRUG: Placebo
DRUG: cetuximab
RADIATION: IMRT

Sponsor

Groupe Oncologie Radiotherapie Tete et Cou